We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vume... Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021. Show more
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA PR...
New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZAReductions in biomarker...
New data advances understanding of new approaches to treating Alzheimer’s diseaseResearch on disease progression could help inform future clinical trials CAMBRIDGE, Mass., March 04, 2024 (GLOBE...
SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe1With QALSODY, Biogen has advanced the role of neurofilament in the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 9.92 | 5.17205422315 | 191.8 | 205.7499 | 189.44 | 1791153 | 196.27305281 | CS |
4 | -15.64 | -7.1954361428 | 217.36 | 217.57 | 189.44 | 1256665 | 201.168752 | CS |
12 | -43.68 | -17.7995110024 | 245.4 | 249.33 | 189.44 | 1270224 | 216.68137645 | CS |
26 | -48.42 | -19.3571599904 | 250.14 | 268.74 | 189.44 | 1168895 | 230.04527672 | CS |
52 | -89.33 | -30.6923209071 | 291.05 | 319.76 | 189.44 | 1104177 | 253.61146351 | CS |
156 | -62.73 | -23.7209302326 | 264.45 | 468.2499 | 187.16 | 1231723 | 266.08143664 | CS |
260 | -22.31 | -9.95848770254 | 224.03 | 468.2499 | 187.16 | 1382846 | 269.56279834 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions